Biomarkers and Cardiac CT

Maastricht University Medical Centre (MUMC)

Status: Enrolling

Conditions: Coronary Artery Disease; Atherosclerosis

Treatments: Biological: Venous blood sampling prior to CCTA.

Study type: Observational

Funder types: Other

Identifiers

NCT02381301

METC 14-4-117

Details and patient eligibility

About

Coronary artery disease (CAD) is the leading cause of morbidity and mortality in developed countries. In addition, many patients suffer from valvular and aortic disease. Although various tools are available to identify patients with cardiovascular (CV) disease at risk for major adverse cardiac events (MACE), the identification of these patients remains a clinical challenge.

One promising avenue is the use of different serum biomarkers involved in atherothrombosis which could provide an easy and cost-effective step in risk stratification.

Enrollment: 5,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients referred from the Cardiology clinic for routine CCTA.

Exclusion criteria

• Pregnancy
• Severe renal insufficiency
• Severe allergy to contrast medium
• Inability to obtain informed consent
• Age below 18 years

Trial design

5,000 participants in 1 patient group

Venous blood sampling prior to CCTA.

Description:

In patients undergoing routine Cardiac Computed Tomography Angiography (CCTA) and given written informed consent blood sampling will be performed. The samples will be stored for a period of 15 years at the Biobank for future analyses.

Treatment:

Biological: Venous blood sampling prior to CCTA.